Showing results (361-370 of 412) with videos related to

Sort By:
Pageof 42
The Lancet. Haematology|January 15, 2018
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trialRami Komrokji, Guillermo Garcia-Manero, Lionel Ades, et al.
Blood Neoplasia|June 2, 2025
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.
Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.
FEBS Letters|November 24, 2016
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitorsTaekyu Lee, Zhiguo Bian, Bin Zhao, et al.
The New England Journal of Medicine|June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid LeukemiaGail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
Leukemia & Lymphoma|July 29, 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemiaKendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, et al.
American Journal of Obstetrics & Gynecology MFM|December 9, 2023
Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birthIrene Cetin, Susan E Carlson, Christy Burden, et al.
Ejhaem|July 18, 2022
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect<sup>®</sup> MDS/AML Disease RegistryDaniel A Pollyea, Tracy I George, Mehrdad Abedi, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Pageof 42